IPO pricing
6 articles
Retension Pharmaceuticals Files 424B4 Prospectus for IPO
Retension Pharmaceuticals filed its final 424B4 prospectus with the SEC on Oct. 9, 2026. Here is what the filing signals and what to check in the pricing terms.
Bluerock Acquisition II IPO Pricing: $150 Million, Trust at $10.05
Bluerock Acquisition Corp. II priced a $150 million SPAC IPO on Nasdaq that closed at $172.5 million, with a $10.05-a-unit trust and a 21-month deadline.
Inflection Point VIII IPO Pricing: $287.5 Million on Nasdaq
Inflection Point Acquisition Corp. VIII priced a SPAC IPO at $10 a unit on Nasdaq and, with the over-allotment exercised in full, raised $287.5 million.
NorthStrive Acquisition IPO Pricing: $100 Million, Nasdaq
NorthStrive Acquisition Corp I priced a $100 million SPAC IPO at $10 a unit on Nasdaq and put the full amount in trust, with a 12-month window plus extensions.
OceanLight Acquisition IPO Pricing: $100 Million on Nasdaq
OceanLight Acquisition Corp priced a $100 million SPAC IPO at $10 a unit on Nasdaq, with rights and warrants in each unit and a closing 8-K detailing the sale.
Samos Energy SPAC IPO Pricing: $10 a Unit on the NYSE
Samos Energy Acquisition Corp priced its IPO at $10.00 a unit on the NYSE with Cantor as sole bookrunner, and an 8-K details trust funding and warrants.